Press Releases

FDA Response on CBD Fails Consumers and Industry and Highlights Agency’s Four Years of Inaction

CRN expressed dismay today about FDA’s denial of its 2020 citizen petition calling on the agency to create a regulatory pathway to legally market dietary supplements containing hemp-derived cannabidiol (CBD) and the agency’s separate announcement that FDA “has concluded a new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks.”

CRN Foundation’s Economic Report Shows the Potential of Certain Dietary Supplements To Reduce Medical Costs Associated with Coronary Artery Disease

Observance of February as Heart Month can be a reminder of the cost-saving potential of evidence-backed dietary supplements to help reduce the health impacts—and the healthcare costs—of coronary artery disease. The CRN Foundation’s recent Health Care Cost Savings report, Supplement to Savings (“S2S”), identified up to $17.74 billion in annual net savings if specific dietary supplements (omega-3 fatty acids, magnesium, vitamin K2 and soluble fiber) are used by the at-risk target populations most susceptible to coronary artery disease (CAD). The study, commissioned by the CRN Foundation and conducted by Frost & Sullivan, provides analysis on the risk reduction effects supplementation can have on specific chronic illnesses or diseases, including CAD. The Foundation announced the overall findings including insights on the analysis in August 2022.